FLOT4

Brief title: FLOT4
Design: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
No of patients: 658
Status: Recruiting

A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach. Primary endpoint is disease free survival. Secondary outcome measures are histological regressions rate, overall survival, perioperative morbidity and mortality and R0-resection rate.

LKP:
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main

More information

Nepafox

Brief title: Nepafox
Design: A randomized, multicentre phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in patients with resectable pancreatic cancer.
No of patients: 126 (phase II)
Status: Under preparation

Double blind phase II/III study to determine the overal survival as the primary endpoint. Secondary endpoints are the progression free survival and the mortality/morbidity.

LKP:
Wael Hozaeel
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main

FLOT3

Brief title: FLOT3
Design: Prospective study with 5-FU, Leucovirin, Oxaliplatin and Docetaxel (FLOT) in patients with locally advanced, limited metastatic or extensive adenocarcinoma of the stomach or esophagogastric junction
No of patients: 250
Status: Completed

Patients with locally advanced or metastatic gastric carcinoma or carcinoma of the esophagogastric junction without prior palliative therapy will be treatedin this multicentre phase II study. Primary outcome measure was overall survival, secondary outcome measures were quality of life, pregression free survival and rate of R0-resections, rate of pathological remissions and perioperative morbidity and mortality in stratum A and B

LKP:
Prof. Dr. S.E. Al-Batran
Institut für Klinisch-Onkologische Forschung
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main

More information